Compare Amphastar Pharmaceuticals Inc (AMPH) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs JPMorgan Equity Premium Income ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while JPMorgan Equity Premium Income ETF trades at $57.87. The key difference: JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | JEPI | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $59.88 |
52-Week Low | $16.87 | $55.29 |
Enterprise Value | $1.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
JEPI trades at $57.58, showing minimal daily change. Technical indicators are bullish overall, with strong moving average support but a neutral oscillator reading. Recent news highlights its role in income strategies, though some articles note underperformance versus peers. The ETF's covered-call strategy provides monthly income but may limit capital appreciation.
The outlook is mixed: JEPI offers reliable income with a covered-call approach, appealing for risk-averse investors. However, competition from higher-yielding ETFs and potential tax inefficiencies pose risks. Investors should weigh income stability against growth opportunity costs in a rising market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
